Opendata, web and dolomites

DIAMONDS SIGNED

Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DIAMONDS" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 23˙839˙940 €
 EC max contribution 22˙582˙021 € (95%)
 Programme 1. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme IA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 6˙577˙019.00
2    SERVIZO GALEGO DE SAUDE ES (Santiago de Compostela) participant 2˙400˙000.00
3    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 1˙800˙000.00
4    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 1˙525˙000.00
5    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) participant 1˙300˙000.00
6    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 800˙000.00
7    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 800˙000.00
8    RIGAS STRADINA UNIVERSITATE LV (RIGA) participant 650˙000.00
9    UNIVERZITETNI KLINICNI CENTER LJUBLJANA SI (LJUBLJANA) participant 650˙000.00
10    MICROPATHOLOGY LIMITED UK (COVENTRY) participant 550˙000.00
11    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 500˙001.00
12    THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST UK (NEWCASTLE-UPON-TYNE) participant 404˙613.00
13    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 400˙000.00
14    BIOMERIEUX SA FR (Marcy l'Etoile) participant 400˙000.00
15    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 400˙000.00
16    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 400˙000.00
17    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 400˙000.00
18    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 400˙000.00
19    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 400˙000.00
20    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 400˙000.00
21    UNIVERSITAET BERN CH (BERN) participant 400˙000.00
22    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 400˙000.00
23    SKYLINEDX B.V. NL (ROTTERDAM) participant 249˙999.00
24    EUROPEAN MOLECULAR BIOLOGY LABORATORY DE (HEIDELBERG) participant 200˙000.00
25    BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) AT (GRAZ) participant 130˙000.00
26    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 45˙386.00
27    NATIONAL CHENG KUNG UNIVERSITY TW (Tainan) participant 0.00
28    UNIVERSITY OF MELBOURNE AU (MELBOURNE) participant 0.00

Map

 Project objective

Our proposal will address the challenge of bringing personalised medicine into routine use in EU healthcare systems for diagnosis and treatment of common infectious and inflammatory diseases, which account for a up to a third of all medical encounters in primary care and hospital. The diagnostic process in clinical medicine has been based on recognition of a constellation of symptoms and clinical signs, supported by laboratory tests. However, a definitive diagnosis is currently made in only a minority of patients presenting to healthcare with suspected infection or inflammation. We have previously shown that individual infectious and inflammatory diseases are characterised by unique patterns of host gene expression, and that diagnosis of individual diseases can be based on small numbers of uniquely expressed genes. We propose a new diagnostic classification of infectious and inflammatory diseases, based on the discriminatory ability of a minimal set of genes, which is able to distinguish all common conditions simultaneously, an approach we call Personalised Molecular Signature Diagnosis (PMSD). In partnership with 22 hospitals in 11 EU countries, and biotechnology groups in academia, SMEs and industry, we will develop a device to detect genes required for PMSD. We will then undertake a large-scale pilot demonstration in diverse healthcare settings in Europe, to establish the benefit to patients, reduction in healthcare resource use, cost effectiveness and acceptability to patients and carers, of PMSD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIAMONDS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIAMONDS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.6.)

SAPHIRE (2018)

Securing Adoption of Personalised Health in REgions

Read More  

GC_1000 (2020)

GROUP CARE FOR THE FIRST 1000 DAYS (GC_1000): If it takes a village to raise a child, group care is the first step

Read More  

EULAC-PerMed (2019)

Widening EU-CELAC policy and research cooperation in Personalised Medicine

Read More